South Africa can afford antiretroviral treatment
BARCELONA – Based on existing resources, South Africa can ‘easily afford’ to provide anti-retroviral therapy to between 60 000 and 70 000 people in the next five years.
This was the conclusion from a study by Dr Chris Kenyon of the Health Systems Trust and Dr Andrew Boulle, a registrar in the School of Public Health at the University of Cape Town, presented at the 14th World Conference on AIDS in Barcelona yesterday (Tuesday).
The model for treatment was premised on the purchase of generic medicines. Only half as many people could be treated if generics were not secured.
In their study, Boulle and Kenyon showed that it would cost US $ 25 million to treat between 60 000 and 70 000 people by 2007. A large proportion of these costs would be offset by the savings gained from people who would otherwise report sick to hospitals and clinics requiring treatment for AIDS related illnesses.
Among the proven benefits of antiretroviral therapy is the boost it gives to the body’s immune system enabling it to resist the opportunistic infections that affect people who have AIDS.
Boulle said the model he presented was ‘deliberately conservative’ and was based on current health department budgets, in order not to make unrealistic claims on the South African fiscus.
Boulle said he believed government should demonstrate its commitment to treating people who were sick with AIDS by using its own resources to begin an antiretroviral treatment programme.
‘It is cynical to make a treatment programme contingent on getting outside funds,’ he said. ‘We don’t need any outside money to begin treatment. If we raised extra resources we could extend the programme.’
Boulle cautioned that although the model suggested 60 000 people could be treated, he was not advocating this precise number .
‘We are wanting to demonstrate that a limited programme offering antiretroviral therapy is definitely possible,’ said Boulle.
‘Ideally we’d want to treat as many people as possible. The number we can treat would depend on policy choices and a commitment to raise additional sources either internally or externally.’
Author
Republish this article
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Unless otherwise noted, you can republish our articles for free under a Creative Commons license. Here’s what you need to know:
You have to credit Health-e News. In the byline, we prefer “Author Name, Publication.” At the top of the text of your story, include a line that reads: “This story was originally published by Health-e News.” You must link the word “Health-e News” to the original URL of the story.
You must include all of the links from our story, including our newsletter sign up link.
If you use canonical metadata, please use the Health-e News URL. For more information about canonical metadata, click here.
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week”)
You have no rights to sell, license, syndicate, or otherwise represent yourself as the authorized owner of our material to any third parties. This means that you cannot actively publish or submit our work for syndication to third party platforms or apps like Apple News or Google News. Health-e News understands that publishers cannot fully control when certain third parties automatically summarise or crawl content from publishers’ own sites.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
If you share republished stories on social media, we’d appreciate being tagged in your posts. You can find us on Twitter @HealthENews, Instagram @healthenews, and Facebook Health-e News Service.
You can grab HTML code for our stories easily. Click on the Creative Commons logo on our stories. You’ll find it with the other share buttons.
If you have any other questions, contact info@health-e.org.za.
South Africa can afford antiretroviral treatment
by , Health-e News
July 10, 2002